n.a. (FURX)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Shares Outstanding 10.82M
Div & Yield N.A. (N.A)
Furiex Pharmaceuticals’ Antibiotic Program Featured In Two Abstracts At 21st ECCMID/27th ICC Joint Congress

Furiex Pharmaceuticals’ Antibiotic Program Featured In Two Abstracts At 21st ECCMID/27th ICC Joint Congress

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today announced that two abstracts featuring its antibiotic candidate JNJ-Q2 will be presented at the 2011 joint meeting of the European Congress of Clinical Microbiology and...

Furiex Reports First Quarter 2011 Financial Results

Furiex Reports First Quarter 2011 Financial Results

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today reported its financial and operating results for the quarter ended March 31, 2011.

Furiex Acquires Full Exclusive License Rights To Develop And Commercialize JNJ-Q2 (fluoroquinolone)

Furiex Acquires Full Exclusive License Rights To Develop And Commercialize JNJ-Q2 (fluoroquinolone)

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with...

Furiex Pharmaceuticals Announces First Quarter 2011 Earnings Release And Conference Call

Furiex Pharmaceuticals Announces First Quarter 2011 Earnings Release And Conference Call

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) will release its first quarter 2011 financial results on Thursday, April 28, 2011, after the market closes.

Furiex Confirms Takeda Receives Approval Of Additional NESINA® Combination Therapies With Sulfonylurea And Biguanide For Type 2 Diabetes In Japan

Furiex Confirms Takeda Receives Approval Of Additional NESINA® Combination Therapies With Sulfonylurea And Biguanide For Type 2 Diabetes In Japan

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today confirmed that Takeda Pharmaceutical Company Limited’s applications for two additional indications for “NESINA ®” (alogliptin), combination therapy ...

Furiex Reports Fourth Quarter 2010 Financial Results

Furiex Reports Fourth Quarter 2010 Financial Results

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today reported its financial and operating results for the quarter ended December 31, 2010.

Furiex Pharmaceuticals, Inc. Announces Presentation At The BIO CEO & Investor Conference On February 15, 2011

Furiex Pharmaceuticals, Inc. Announces Presentation At The BIO CEO & Investor Conference On February 15, 2011

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX), a drug development collaboration company, announced that June Almenoff, Ph.

Furiex Pharmaceuticals Announces Fourth Quarter 2010 Earnings Release And Conference Call

Furiex Pharmaceuticals Announces Fourth Quarter 2010 Earnings Release And Conference Call

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) will release its fourth quarter 2010 financial results on Monday, February 21, 2011, after the market closes.

Furiex Receives FDA Fast Track Designation Of MuDelta For The Treatment Of Diarrhea-Predominant Irritable Bowel Syndrome

Furiex Receives FDA Fast Track Designation Of MuDelta For The Treatment Of Diarrhea-Predominant Irritable Bowel Syndrome

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today announced that its novel diarrhea-predominant irritable bowel syndrome treatment called MuDelta, now in Phase II clinical trials, has been granted Fast Track ...

Dr. Steve Kaldor Joins Furiex Board Of Directors

Dr. Steve Kaldor Joins Furiex Board Of Directors

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced today that Stephen W.

Furiex Reports Third Quarter 2010 Financial Results

Furiex Reports Third Quarter 2010 Financial Results

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today reported its financial and operating results for the quarter ended September 30, 2010.

Furiex Reports Positive Phase II Results For Broad Spectrum Quinolone Antibiotic In Complicated Skin Infections

Furiex Reports Positive Phase II Results For Broad Spectrum Quinolone Antibiotic In Complicated Skin Infections

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced positive top-line results from its Phase II clinical trial involving the investigational antibacterial drug JNJ-Q2 for the treatment of acute bacterial skin and ...

Furiex Pharmaceuticals Announces Third Quarter 2010 Earnings Release, Webcast And Conference Call

Furiex Pharmaceuticals Announces Third Quarter 2010 Earnings Release, Webcast And Conference Call

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) will release its third quarter 2010 financial results on Wednesday, November 10, 2010, after the market closes.

Furiex Pharmaceuticals, Inc. To Present At Rodman & Renshaw Annual Global Investment Conference In New York September 12-15, 2010

Furiex Pharmaceuticals, Inc. To Present At Rodman & Renshaw Annual Global Investment Conference In New York September 12-15, 2010

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) announced today that it will present at Rodman & Renshaw’s 12th Annual Healthcare Conference in New York on Monday, September 13, 2010, at 2:50 p.

David Einhorn: Long on Apple

Famous short-seller David Einhorn of Greenlight Capital bought Apple and increased holdings in Microsoft during the second quarter, according to latest portfolio disclosures with the Securities and Exchange Commission.

Furiex Reports Second Quarter 2010 Financial Results

Furiex Reports Second Quarter 2010 Financial Results

In the CONSOLIDATED STATEMENTS OF OPERATIONS, under Weighted-average shares used to compute net income (loss) per basic and diluted share, the Three Months Ended June 30, 2009 should read: 9,881 (sted 9,88).

Furiex Pharmaceuticals Announces Second Quarter 2010 Earnings Release And Conference Call

Furiex Pharmaceuticals Announces Second Quarter 2010 Earnings Release And Conference Call

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) will release its second quarter 2010 financial results on Wednesday, August 11, 2010, after the market closes.

Furiex Pharmaceuticals Announces Issuance Of U.S. Patent For Dapoxetine Method Of Treatment

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced today that the United States Patent and Trademark Office issued a patent on May 18, 2010, for the method for treatment of premature ejaculation using dapoxetine.